Gamma Knife for Meningioma: Control Rates, and When It Beats Surgery or Watching

For a benign (WHO grade I) meningioma, Gamma Knife gives roughly 85 to 100% control at 5 years (median about 94%) with a margin dose of 12 to 16 Gy, and it is chosen instead of surgery or observation when the tumour is small to moderate, well seen, and either causing symptoms or growing. A meningioma is a tumour of the membranes covering the brain and spinal cord, and most are benign and slow-growing¹. Radiosurgery does not remove it; it stops it growing, which for this tumour is usually enough².

I was treated for an acoustic neuroma rather than a meningioma, so I write this as a fellow patient who has been through the same machine and the same long planning wait, not as someone who had this exact tumour. What struck me reading around the two conditions is how similar the decision feels: a small benign lump, three reasonable options on the table, and a team weighing them from the scans. This is the plain account of how that decision goes for meningioma. For the wider picture of the treatment itself, start with Gamma Knife radiosurgery.

How well does Gamma Knife control a benign meningioma?

For grade I meningioma, Gamma Knife achieves roughly 85 to 100% local control at 5 years, with a median across studies of about 94%, using a margin dose of 12 to 16 Gy. That is a strong result for a single day-case treatment, and it is why radiosurgery is now a mainstream option for these tumours rather than a last resort². Control here means the tumour stops enlarging; it does not mean it disappears. The mass usually stays visible on follow-up scans, and stability or slow shrinkage is the success you are looking for.

The figures come from pooled data across many centres, so treat them as a range rather than a promise. The exact odds for one person depend on the tumour’s size, its position, and how long it is followed. This is the same distinction I had to make peace with for my own tumour: radiosurgery works gradually, and the scan you leave with will still show the lesion.

When is radiosurgery chosen over surgery for meningioma?

Radiosurgery is chosen when the meningioma is small to moderate, generally 3 to 3.5 cm or less (about 10 to 15 cc), well seen on imaging, and does not need immediate decompression or a tissue diagnosis. Single-session Gamma Knife suits targets in that size range; larger ones are usually operated on, or the dose is staged over a few sessions³. The appeal is obvious: no incision, no general anaesthetic, and home the same day.

Surgery keeps the edge in three situations. First, when the tumour is large or pressing on the brain and needs the mass taken out quickly to relieve pressure. Second, when the team needs a tissue sample to confirm the grade, since imaging alone cannot always tell a benign meningioma from a more aggressive one. Third, when the location makes safe complete removal realistic and durable. For the fuller comparison of the two approaches, incision against latency, see Gamma Knife versus surgery. Whether a given tumour even qualifies for radiosurgery is set out in am I a candidate for Gamma Knife.

When is watching and waiting the right call?

Observation is the standard approach for a small, symptom-free meningioma found by chance, because many never grow enough to cause trouble and the risks of treating can outweigh the risk of watching. These tumours are common incidental findings, and being benign and slow-growing, a great many can simply be monitored¹. Surveillance means periodic MRI to track size, not ignoring the tumour.

Treatment moves onto the table when a scan shows the tumour growing, when it starts causing symptoms, or when it sits somewhere that even small growth would be dangerous, such as near the optic nerves. The judgement between acting now and monitoring is exactly the one covered in watch and wait versus Gamma Knife. Of the three options, this is the one patients most often overlook, assuming a brain tumour must always be treated at once. The emotional side of a diagnosis makes “we will watch it” a surprisingly hard sentence to accept, and I remember how counterintuitive the idea of deliberate non-treatment felt.

Why grade II and III meningiomas are different

Atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas grow faster and recur far more often than grade I, so control after radiosurgery is markedly worse than the 85 to 100% seen for benign tumours. The grade, confirmed under a microscope, changes everything about the plan. Where a grade I tumour may be well handled by a single 12 to 16 Gy treatment, higher-grade tumours behave more like cancers and need a more aggressive strategy².

For these, the usual route is surgery to remove as much as possible, followed by fractionated radiotherapy, with radiosurgery reserved for specific situations decided case by case. This is one reason a biopsy or resection can matter: you cannot always tell the grade from a scan, and the grade drives the whole approach. When a single high dose is split into several sessions, the terminology shifts from radiosurgery to stereotactic radiotherapy⁴.

What the dose is, and what the day looks like

A benign meningioma is treated with a margin dose commonly of 12 to 16 Gy in a single session, planned to spare nearby structures such as the optic nerves and brainstem. The team, a neurosurgeon, a radiation oncologist and a medical physicist, chooses the exact figure to balance tumour control against protecting healthy tissue². Tumours very close to the optic apparatus may be fractionated instead, precisely because those nerves tolerate only so much radiation in one hit.

The day itself follows the same shape as for any Gamma Knife target: fitting the frame, imaging, a long wait while the dose is planned, then the treatment while you are awake, all typically completed in one day³. The planning wait was the part of my own day I was least prepared for, sitting with the frame on while people I could not see worked out where every beam would go. For that account see the day in the Gamma Knife frame and Gamma Knife planning and dose.

Risks specific to meningioma radiosurgery

Early side effects are usually mild, and the most important delayed risk is radiation necrosis, roughly 5 to 25% depending on the size of the target and the dose; for skull-base meningiomas, effects on nearby cranial nerves are the other thing to weigh. No high-dose radiation treatment is free of risk, and honesty here matters more than reassurance⁵. In the first hours to weeks, fatigue, headache and mild brain swelling managed with steroids are the common ones.

Because meningiomas often sit at the skull base near nerves, the specific concern is a change in a cranial nerve close to the target, for example affecting vision or hearing, which is why position drives the dose and the choice of single versus fractionated treatment. The full breakdown is in Gamma Knife risks and side effects, and the delayed effect people worry about most is explained calmly in radiation necrosis, what I learned. The fatigue that nobody flagged for me is covered in fatigue after Gamma Knife.

How the result is followed up

Because a benign meningioma changes slowly, over 1 to 3 years, the result is judged from serial follow-up MRI rather than from how you feel, and the tumour usually stays visible throughout. Stability or gradual shrinkage on repeated scans is the sign the treatment worked⁴. Follow-up is typically an office visit at about a month, then MRIs at intervals such as 3, 6 and 12 months, spacing out over subsequent years³.

The waiting between scans was harder for me than the treatment day, and it is a common experience: see radiosurgery and scanxiety. The knowledge that a still-visible tumour on a scan can be a good result, not a failure, is one I wish I had held onto earlier, and it is set out in Gamma Knife results and follow-up.